Apollomics, Inc. (APLM)
| Previous Close | 0.4190 |
| Open | 0.4191 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4021 - 0.4230 |
| 52 Week Range | 0.4000 - 6.4500 |
| Volume | |
| Avg. Volume | 206,537 |
| Market Cap | 36.335M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.75 |
GlobeNewswireApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers,
- GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancerFOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American A
- GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif. Copies of the posters will be made available on the Apollomics website following the presentation at ir.a
